| Schedule Of Segment Reporting Information |
The following table presents information by reportable operating segment for the three and six months ended June 30, 2019 and 2018 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended June 30, |
|
Six months ended June 30, |
|
2019 |
|
2018 |
|
2019 |
|
2018 |
Consumer Products |
|
|
|
|
|
|
|
Product sales, net |
$ |
16,854 |
|
|
$ |
12,349 |
|
|
$ |
31,765 |
|
|
$ |
20,419 |
|
Gross profit |
11,951 |
|
|
9,060 |
|
|
22,510 |
|
|
14,622 |
|
Research and development expense |
679 |
|
|
76 |
|
|
1,378 |
|
|
193 |
|
Selling, general and administrative expense |
8,999 |
|
|
5,320 |
|
|
27,584 |
|
|
10,046 |
|
Operating income (loss) |
$ |
2,273 |
|
|
$ |
3,664 |
|
|
$ |
(6,452 |
) |
|
$ |
4,383 |
|
|
|
|
|
|
|
|
|
Specialty Pharmaceutical |
|
|
|
|
|
|
|
Product sales, net |
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Gross profit |
— |
|
|
— |
|
|
— |
|
|
— |
|
Research and development expense |
1,009 |
|
|
366 |
|
|
1,652 |
|
|
403 |
|
Selling, general and administrative expense |
10 |
|
|
1 |
|
|
20 |
|
|
15 |
|
Operating loss |
$ |
(1,019 |
) |
|
$ |
(367 |
) |
|
$ |
(1,672 |
) |
|
$ |
(418 |
) |
|
|
|
|
|
|
|
|
Total |
|
|
|
|
|
|
|
Product sales, net |
$ |
16,854 |
|
|
$ |
12,349 |
|
|
$ |
31,765 |
|
|
$ |
20,419 |
|
Gross profit |
11,951 |
|
|
9,060 |
|
|
22,510 |
|
|
14,622 |
|
Research and development expense |
1,688 |
|
|
442 |
|
|
3,030 |
|
|
596 |
|
Selling, general and administrative expense |
9,009 |
|
|
5,321 |
|
|
27,604 |
|
|
10,061 |
|
Operating income (loss) |
$ |
1,254 |
|
|
$ |
3,297 |
|
|
$ |
(8,124 |
) |
|
$ |
3,965 |
|
|